Liquid Biopsies & Companion Diagnostics

Liquid Biopsies and Companion Diagnostics 2014 brings together academic researchers, industry researchers, as well as biotechnology and pharmaceutical companies to explore the expanding and evolving field whereby Circulating Biomarkers of various classes are being evaluated for their potential to be developed into diagnostics for cancer as well as other disease classes.

Agenda Topics - Liquid Biopsies:

- Analysis of Somatic Mutations in ctDNA and CTCs
- Circulating Tumor Cells (CTCs): Potential as Prognostic or Predictive Biomarkers
- Circulating Tumor DNA (ctDNA): Potential for Development of Liquid Biopsies
- Emerging Technology Platforms for Interrogating Circulating Biomarkers and Developing Liquid Biopsies
- Extracellular Nucleic Acids in the Circulating (ctDNA, Circulating Free DNA, Extracellular RNA)
* Enveloped within Extracellular Vesicles (such as Exosomes, Microvesicles, EVs)
* Free in the Circulation


Agenda Topics - Companion Diagnostics:

- CDx in Emerging Markets (EU and Asia/Pacific)
- Circulating Biomarkers vs. Tissue-based Biomarkers for Companion Diagnostics Development
- Clinical Utility and Reimbursement for Companion Diagnostics: Payor Perspective
- Companion Diagnostics Regulatory Environment: Taking a Biomarker to CDx to Approval
- Converting LDTs to FDA Approved Tests
- Diagnostics and Pharmaceutical Companies Partnering for Companion Diagnostics Development
-Epigenetic Modifications (Hypermethylation of specific Genes) as Biomarkers for Diagnostics Development
- Next Generation Sequencing in Companion Diagnostics
- Platform Technologies for Building Companion Diagnostics
- Potential of microRNAs as Biomarkers for Diagnostics Development
- Protein Biomarkers versus Nucleic Acid Biomarkers for Companion Diagnostics Development
- The Future of Companion Diagnostics and New Areas of Development
* Cardiovascular and Metabolic Diseases
* Infectious Diseases
* Neuroscience
- US vs. EU Regulatory Landscape for Companion Diagnostics

+ show speakers and program
Keynote Speakers - Liquid Biopsies

- Nicholas Dracopoli
Vice President/Head, Johnson & Johnson
- Michael Heller
Professor, University of California San Diego
- Dave Hoon
Director, Molecular Oncology and Chief of Scientific Intelligence, John Wayne Cancer Institute
- Ruth Katz
Professor of Pathology, Chief Image Analysis Laboratory, MD Anderson Cancer Center, University of Texas
- Walter Koch
VP, Head of Global Research, Roche Molecular Systems
-Klaus Pantel
Director, University Medical Center Hamburg Eppendorf
- Oscar Puig
Biomarker Leader, Hoffmann-La Roche Translational and Clinical Research Center

Other Speakers:

- Charles Cantor, Chief Scientific Officer, Sequenom
Maximilian Diehn, Assistant Professor of Radiation Oncology, Stanford University School of Medicine
- Kenneth Witwer, Assistant Professor, Johns Hopkins University School of Medicine
Shlomit Kenigsberg, Senior Researcher, Create Fertility Centre Canada
- Klaus Pantel, Director, University Medical Center Hamburg Eppendorf
- Martin Siaw, Associate Scientific Director, Quest Diagnostics Nichols Institute
- Dolores Di Vizio, Associate Professor, Cedars-Sinai Medical Center
- Edith Szafer-Glusman, Senior Research Associate, Oncology Biomarker Development, Genentech, Inc.
- Phil Stephens, Chief Scientific Officer, Foundation Medicine
- Chris Karlovich, Principal Scientist, Molecular Diagnostics, Clovis Oncology
- Martin Beaulieu, Director, MicroMarkers, Regulus Therapeutics Inc.
- Lyle Arnold, CSO and Sr. Vice President, R&D, Biocept, Inc.
- Theresa Zhang, Vice President-Research Services, Personal Genome Diagnostics


Keynote Speakers - Companion Diagnostics:

- Yoshiya Oda
President, Eisai, Inc
- Scott Patterson
Executive Director, Medical Sciences, Amgen, Inc.
- Robert Wassman
Chief Medical Officer, Rosetta Genomics

Other Speakers:

- Scott Patterson, Executive Director, Medical Sciences, Amgen, Inc.
- Wolfgang Sadee, Professor, Ohio State University
- Matthew Marton, Director, Clinical Genomics, Merck Research Laboratories
- Nicole St Jean, Corporate Business Development, AstraZeneca Pharmaceuticals LP
- Nicholas Dracopoli, Vice President/Head, Johnson & Johnson
- Frank Ong, Associate Director, Medical Affairs, Illumina, Inc.
- Charles Mathews, Vice President, Boston Healthcare
- Sylvie Le Gledic, Director IVD/CDx, Voisin Consulting Life Sciences
- Thomas Li, Chief Technology Officer of the Diagnostics and Devices Hub, A*STAR Singapore
- Dan Rhodes, Head of Oncology Strategy, Thermo Fisher Scientific
- John Schilling, Director & Advisor of Diagnostics, Eli Lilly & Co.
- David Whyte, VP, Global Development, Amoy Diagnostics, Co LTD
- Shawna Gvazdauskas, Global Head of Device Strategy, External Opportunities & IP Liaison, Sanofi
- Jonathan Pan, Director, Oncology Companion Diagnostic and Disease Strategy, GlaxoSmithKline Oncology
Lesley Farrington, Director, Regulatory Affairs, Roche Molecular Systems
Frederic Sweeney, Senior Director of Business Development, T2 Biosystems
Anthony Altar, Chief Science Officer and Sr. Vice President, Assurex Health, Inc.




27 Oct - 27 Oct 2014
San Diego
United States of America
meeting website